Rotavirus remains a major cause of acute gastroenteritis and hospitalization among young children worldwide, particularly where routine vaccination is not widely implemented. This retrospective hospital-based study evaluated children aged 1 month to 5 years hospitalized with laboratory-confirmed rotavirus gastroenteritis, focusing on demographics, clinical outcomes, length of stay, vaccination status, and direct medical costs. Among 540 rotavirus-positive children, 434 were outpatients, 20 received day-care treatment, and 77 were hospitalized. The median age was 8 months; 88.3% were younger than 24 months, and admissions clustered in spring and winter. The median hospital stay was 6 days, and the median hospitalization cost was $125 (range: $35.1-$414), with higher costs among those hospitalized for more than 7 days (P < .001). None of the patients had received rotavirus vaccination. Vaccine prices were comparable to or lower than median hospitalization costs, supporting the potential cost-effectiveness of including rotavirus vaccine in the national immunization program.
TateJEBurtonAHBoschi-PintoC, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(2):136-141.
2.
NirmalKGangarS.Rotaviral Diseases and Their Implications. London: IntechOpen; 2023.
3.
CunliffeNAKilgorePEBreseeJS, et al. Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull World Health Organ. 1998;76(5):525-537.
4.
TroegerCKhalilIARaoPC, et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr. 2018;172(10):958-965.
5.
LeungDTChistiMJPaviaAT.Prevention and control of childhood pneumonia and diarrhea. Pediatr Clin North Am. 2016;63(1):67-79.
6.
GüzelMAkpınarOKılıçMB.Prevalence of rotavirus-associated acute gastroenteritis cases in early childhood in Turkey: meta-analysis. Children. 2020;7(10):159.
7.
TapisizABedir DemirdagTCura YaylaBC, et al. Rotavirus infections in children in Turkey: a systematic review. Rev Med Virol. 2019;29(1):e2020.
8.
BakirMStandaertBTurelOBilgeZEPostmaM.Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model. Vaccine. 2013;31(6):979-986.
9.
GönüllüESoysalAYıldızİKaraböcüoğluM.Impact of self-financed rotavirus vaccination on acute gastroenteritis in young children in Turkey. Hum Vaccin Immunother. 2021;17(2):510-516.
10.
KoksalTAkelmaAZKoksalAO, et al. Cost-effectiveness of rotavirus vaccination in Turkey. J Microbiol Immunol Infect. 2017;50(5):693-699.
11.
JitMBilckeJMangenMJ, et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine. 2009;27(44):6121-6128.
12.
RheingansRDAntilLDreibelbisRPodewilsLJBreseeJSParasharUD.Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis. 2009;200(suppl 1):S16-S27.
13.
MoeKHummelmanEGOoWMLwinTHtweTT.Hospital-based surveillance for rotavirus diarrhea in children in Yangon, Myanmar. J Infect Dis. 2005;192(suppl 1):S111-S113.
14.
Van ManNLuan leTTrachDD, et al. Epidemiological profile and burden of rotavirus diarrhea in Vietnam: 5 years of sentinel hospital surveillance, 1998–2003. J Infect Dis. 2005;192(suppl 1):S127-S132.
15.
CeyhanMAlhanESalmanN, et al. Multicenter prospective study on the burden of rotavirus gastroenteritis in Turkey, 2005–2006: a hospital-based study. J Infect Dis. 2009;200(suppl 1):S234-S238.
16.
KurugölZGeylaniSKaracaY, et al. Rotavirus gastroenteritis among children under five years of age in Izmir, Turkey. Turk J Pediatr. 2003;45(4):290-294.
17.
BalkanÇEÇelebiDÇelebiÖAltoparlakÜ. Erzurum’da 0-5 yaş arası çocuklarda rotavirus ve adenovirus sıklığının araştırılması. Türk Mikrobiyol Cem Derg. 2012;42(2):51-54.
18.
ItoHOtabeOKatsumiY, et al. The incidence and direct medical cost of hospitalization due to rotavirus gastroenteritis in Kyoto, Japan, as estimated from a retrospective hospital study. Vaccine. 2011;29(44):7807-7810.
19.
LongSSProberCGFischerM. Principles and Practice of Pediatric Infectious Diseases. 5th ed.Amsterdam, The Netherlands: Elsevier Health Sciences; 2017:5863-5890.
20.
GuarinoAAshkenaziSGendrelD, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr. 2014;59(1):132-152.
21.
HarrisCTurnerTMazzaDWilkinsonF; Health for Kids Guideline Development Groups. Guideline development process for the Health for Kids in the South East project. Aust Fam Physician. 2008;37:2-5.
22.
American Academy of Pediatrics. Rotavirus infections. In: KimberlinDWBaenettEDLynfieldRSawyerMH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. Itasca, IL: American Academy of Pediatrics: 2021:644-648.
23.
GürbüzF.Akut gastroenterit nedeniyle hastaneye yatan hastalarda etkenler ve klinik bulgular: epidemiyolojik çalışma. Türkiye Çocuk Hast Derg. 2010;4:211-218.
24.
JinHWangBFangZ, et al. Hospital-based study of the economic burden associated with rotavirus diarrhea in eastern China. Vaccine. 2011;29(44):7801-7806.
25.
ChenK-TFanSFTangRB, et al. Hospital-based study of the economic burden associated with rotavirus diarrhea in Taiwan. Vaccine. 2007;25(21):4266-4272.
26.
OsanoBOWang’ombeJKKamenwaRWWamalwaD.Cost analysis of care for children admitted to Kenyatta national hospital with rotavirus gastroenteritis. Vaccine. 2011;29(23):4019-4024.
27.
NakagomiOCunliffeNA.Rotavirus vaccines: entering a new stage of deployment. Curr Opin Infect Dis. 2007;20(5):501-507.
28.
Ruiz-PalaciosGMPérez-SchaelIVelázquezFR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11-22.
29.
VesikariTMatsonDODennehyP, et al. Safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33.
30.
TateJEPanozzoCAPayneDC, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics. 2009;124(2):465-471.
31.
MarquisAKochJ.Impact of routine rotavirus vaccination in Germany: evaluation five years after its introduction. Pediatr Infect Dis J. 2020;39(7):e109-e116.
32.
PayneDCBaggsJZerrDM, et al. Protective association between rotavirus vaccination and childhood seizures in the year following vaccination in US children. Clin Infect Dis. 2014;58(2):173-177.
33.
SheridanSLWareRSGrimwoodKLambertSB.Febrile seizures in the era of rotavirus vaccine. J Pediatric Infect Dis Soc. 2016;5(2):206-209.
34.
KristinsdottirIHaraldssonALöveAAsgeirsdottirTLThorsV.Burden of rotavirus disease in young children in Iceland–Time to vaccinate?Vaccine. 2021;39(38):5422-5427.
35.
GiaquintoCVan DammePHuetF, et al. Clinical consequences of rotavirus acute gastroenteritis in Europe, 2004–2005: the REVEAL study. J Infect Dis. 2007;195(suppl 1):S26-S35.
36.
EdwardsCHBekkevoldTFlemE.Lost workdays and healthcare use before and after hospital visits due to rotavirus and other gastroenteritis among young children in Norway. Vaccine. 2017;35(28):3528-3533.
37.
GundesliogluÖOTekinRCevikSPalanciYYazıcıogluA. The effects of nosocomial rotavirus gastroenteritis on the length of hospital stay and cost. J Infect Dev Ctries. 2016;10(2):163-167.
